Compare iShares Global Tech ETF (IXN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares Global Tech ETF trades at $142.56, while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: iShares Global Tech ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| IXN | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $149.74 | $6.79 |
52-Week Low | $94.42 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN trades at $142.54, up 2.24% with strong technical momentum as moving averages signal bullish sentiment. The ETF shows robust technical positioning near resistance levels while maintaining neutral oscillator readings. Recent dividend activity and global tech exposure highlight its investment profile.
Outlook remains cautiously optimistic given high valuations and concentration risks in tech holdings. Key opportunities include AI-driven growth exposure, while risks involve stretched valuations and sector volatility. Analyst consensus suggests holding for strategic tech allocation.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
